natgillin/translations-raw huggingface dataset:
Nivolumab BMS should also be permanently discontinued for Grade 2 or 3 immune-related adverse reactions that persist despite treatment modifications (see section 4.4) or for inability to reduce corticosteroid dose to 10 mg prednisone or equivalent per day. 
Zdravljenje z zdravilom Nivolumab BMS je treba trajno ukiniti tudi v primeru pojava imunsko pogojenih neželenih učinkov stopnje 2 ali 3, ki kljub prilagoditvi zdravljenja ne minejo (glejte poglavje 4.4), ali v primeru, če odmerka kortikosteroida ni mogoče zmanjšati na 10 mg prednizona ali enakovrednega odmerka na dan.
A population PK analysis suggested no difference in CL of nivolumab based on age, gender, race, tumour type, tumour size, and hepatic impairment. 
Analiza podatkov populacijske farmakokinetike ne kaže razlik v očistku nivolumaba glede na starost, spol, raso, vrsto tumorja, velikost tumorja in okvaro jeter.
Diabetes (symptoms include excessive thirst, the passing of a greatly increased amount of urine, increase in appetite with a loss of weight, feeling tired, drowsy, weak, depressed, irritable and generally unwell) or diabetic ketoacidosis (acid in the blood produced from diabetes). 
sladkorno bolezen (simptomi vključujejo prekomerno žejo, izločanje večje količine urina, povečan apetit z zmanjšanjem telesne mase, občutek utrujenosti, zaspanosti, oslabelosti, depresije, razdražljivosti in splošnega slabega počutja) ali diabetično ketoacidozo (kopičenje kisline v krvi zaradi sladkorne bolezni).
These reactions are presented by system organ class and by frequency. 
Neželeni učinki so navedeni po organskih sistemih in pogostnosti.
In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential risk-benefit on an individual basis. 
Zaradi pomanjkanja podatkov je treba nivolumab pri teh populacijah bolnikov uporabljati previdno in pred uvedbo zdravljenja skrbno ovrednotiti razmerje med možnim tveganjem in koristjo pri vsakem bolniku posebej.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika
However, based on its mechanism of action, foetal exposure to nivolumab may increase the risk of developing immune-related disorders or altering the normal immune response and immune-related disorders have been reported in PD-1 knockout mice. 
Vendar pa se na osnovi mehanizma delovanja nivolumaba pri izpostavljenosti ploda nivolumabu lahko poveča tveganje za razvoj imunsko pogojenih bolezni ali spremeni normalni imunski odziv.
Signs and symptoms of hepatitis may include abnormal liver function tests, eye or skin yellowing (jaundice), pain on the right side of your stomach area, or tiredness. 
Znaki in simptomi hepatitisa lahko vključujejo nenormalne izvide preiskav delovanja jeter, rumeno obarvanje oči ali kože (zlatenica), bolečino v desnem predelu trebuha ali utrujenost.
Median time to onset of these endocrinopathies was 17.8 weeks (range: 6.1-33.1). 
Mediani čas do pojava teh endokrinopatij je znašal 17,8 tedna (razpon: 6,1-33,1).
Diarrhoea (watery, loose or soft stools) or any symptoms of inflammation of the intestines (colitis), such as stomach pain and mucus or blood in stool. 
drisko (vodeno, kašasto ali mehko blato) ali kateri koli simptom vnetja črevesa (kolitis), kot so bolečina v trebuhu in sluz ali kri v blatu.
The following immune-related adverse reactions were reported in less than 1% of patients treated with nivolumab in clinical trials across doses and tumour types: pancreatitis, uveitis, demyelination, autoimmune neuropathy (including facial and abducens nerve paresis), Guillain-Barré syndrome, hypopituitarism, and myasthenic syndrome. 
O naslednjih imunsko pogojenih neželenih učinkih so poročali pri manj kot 1 % bolnikov, ki so se v kliničnih preskušanjih zdravili z nivolumabom v različnih odmerkih in zaradi različnih vrst tumorjev: pankreatitis, uveitis, demielinizacija, avtoimunska nevropatija (vključno s parezo obraznega in abducentnega živca), Guillain-Barréjev sindrom, hipopituitarizem in miastenijski sindrom.
These analyses will be conducted in Studies CA 209037 and CA209066 in patients with advanced melanoma. 
Te analize bodo izvedene v študijah CA209037 in CA209066 pri bolnikih z
In case of a severe infusion reaction, nivolumab infusion must be discontinued and appropriate medical therapy administered. 
V primeru pojava hude infuzijske reakcije je treba infundiranje nivolumaba prekiniti in uvesti ustrezno zdravljenje.
Nivolumab BMS infusion must be completed within 24 hours of preparation. 
Raztopina zdravila Nivolumab BMS, pripravljena za infundiranje Infundiranje zdravila Nivolumab BMS je treba dokončati v 24 urah po pripravi.
The recommended dose of Nivolumab BMS is 3 mg/kg administered intravenously over 60 minutes every 2 weeks. 
Priporočeni odmerek zdravila Nivolumab BMS je 3 mg/kg v obliki 60-minutne intravenske infuzije na vsaka 2 tedna.
Signs and symptoms may include abnormal kidney function tests, or decreased volume of urine. 
Znaki in simptomi lahko vključujejo nenormalne izvide preiskav delovanja ledvic ali zmanjšanje volumna izločenega seča.
Signs and symptoms that these glands are not working properly may include fatigue (extreme tiredness), weight change or headache and visual disturbances. 
Znaki in simptomi okvare delovanja teh žlez lahko vključujejo izčrpanost (ekstremno utrujenost), spremembe telesne mase ali glavobol in motnje vida.
Patients should be monitored for signs and symptoms of nephritis and renal dysfunction. 
Bolnike je treba nadzirati glede pojava znakov in simptomov nefritisa in okvare delovanja ledvic.
A total of 272 patients were randomised to receive either nivolumab 3 mg/kg (N = 135) administered intravenously over 60 minutes every 2 weeks or docetaxel (n = 137) 75 mg/m2 every 3 weeks. 
Skupno 272 bolnikov so randomizirali na zdravljenje z nivolumabom v odmerku 3 mg/kg (N = 135) v obliki 60-minutne intravenske infuzije na vsaka 2 tedna ali na zdravljenje z docetakselom (n = 137) v odmerku 75 mg/m2 na vsake 3 tedne.
Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion. 
in PD-L2, ki ju izražajo antigen predstavitvene celice in sta lahko izražena na tumorskih in drugih celicah v mikrookolju tumorja, je zavrtje proliferacije celic T in sekrecije citokinov.
It is to be administered as an intravenous infusion over a period of 60 minutes. 
Aplicirati ga je treba v obliki 60-minutne intravenske infuzije.
• Obligation to conduct post-authorisation measures The MAH shall complete, within the stated timeframe, the below measures: Description 
• Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet Imetnik dovoljenja za promet z zdravilom mora v določenem časovnem okviru izvesti naslednje ukrepe:
Data for the following immune-related adverse reactions are based on patients who received nivolumab 3 mg/kg in two NSCLC studies (CA209017 and CA209063, see section 5.1). 
Podatki v nadaljevanju navedenih imunsko pogojenih neželenih učinkov so bili pridobljeni pri bolnikih, ki so prejemali nivolumab v odmerku 3 mg/kg v dveh študijah NSCLC (študija CA209017 in študija CA209063, glejte poglavje 5.1).
10 mL of concentrate in a 10 mL vial (Type I glass) with a stopper (coated butyl rubber) and a grey flip-off seal (aluminium). 
10 ml koncentrata v 10-ml viali (steklo tipa I) z zamaškom (obložena butilna guma) in sivo dvižno zaporko (aluminij).
If immunosuppression with corticosteroids is used to treat an adverse reaction, a taper of at least 1 month duration should be initiated upon improvement. 
Če se za zdravljenje neželenega učinka uporabi imunosupresivno zdravljenje s kortikosteroidi, je treba po izboljšanju uvesti vsaj 1-mesečno postopno zmanjševanje odmerka.
However, once you are treated with Nivolumab BMS, your doctor may give you corticosteroids to reduce any possible side-effects that you may have during your treatment and this will not impact the effect of the medicine. 
Med zdravljenjem z zdravilom Nivolumab BMS pa vam zdravnik lahko predpiše zdravljenje s kortikosteroidi za ublažitev katerega koli možnega neželenega učinka, ki se lahko pojavi med zdravljenjem.
What Nivolumab BMS looks like and contents of the pack Nivolumab BMS concentrate for solution for infusion (sterile concentrate) is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles. 
Izgled zdravila Nivolumab BMS in vsebina pakiranja Nivolumab BMS koncentrat za raztopino za infundiranje (sterilni koncentrat) je bistra do opalescentna, brezbarvna do svetlorumena tekočina, ki lahko vsebuje manjše število neznatnih delcev.
Patients should be monitored for signs and symptoms of pneumonitis such as radiographic changes (e.g., focal ground glass opacities, patchy filtrates), dyspnoea, and hypoxia. 
Bolnike je treba nadzirati glede pojava znakov in simptomov pljučnice, kot so radiografske spremembe (npr. fokalni vzorci mlečnega stekla, krpasti infiltrati), dispneja in hipoksija.
The management guidelines for these adverse reactions are described in section 4.4. 
Smernice za zdravljenje teh neželenih učinkov so navedene v poglavju 4.4.
Treatment was continued as long as clinical benefit was observed or until treatment was no longer tolerated. 
Zdravljenje je trajalo dokler je bila prisotna klinična korist ali dokler je bolnik zdravljenje prenašal.
Nivolumab is most commonly associated with immune-related adverse reactions. 
Uporaba nivolumaba je bila najpogosteje povezana s pojavom imunsko pogojenih neželenih učinkov.
Musculoskeletal pain is a composite term which includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, pain in jaw, spinal pain. 
Mišično-skeletna bolečina je sestavljen izraz, ki obsega bolečino v hrbtu, bolečino v kosteh, mišično-skeletno bolečino v predelu prsnega koša, mišično-skeletno nelagodje, bolečino v mišicah, bolečino v vratu, bolečino v okončinah, bolečino v čeljusti in bolečino v hrbtenici.
Detailed guidelines for the management of immune-related adverse reactions are described in section 4.4. 
Podrobne smernice za zdravljenje imunsko pogojenih neželenih učinkov so navedene v poglavju 4.4.
The prescriber must discuss the risks of Nivolumab BMS therapy with the patient. 
Zdravnik mora bolniku pojasniti tveganja, povezana z zdravljenjem z zdravilom Nivolumab BMS.
Withdraw the required volume of Nivolumab BMS concentrate using an appropriate sterile 
Potrebni volumen koncentrata zdravila Nivolumab BMS izvlecite v ustrezno sterilno injekcijsko
Most patients 
Pri bolnikih,
Adverse reactions reported in the pooled dataset (n=248) of CA209017 and CA209063 are presented in Table 2. 
Neželeni učinki na osnovi zbranih podatkov (n=248) študije CA209017 in študije CA209063 so prikazani v preglednici 2.
Blockade of PD-L1 signalling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to increase foetal loss. 
Na mišjih modelih gestacije je bilo dokazano, da zavrtje PD-L1 signalne poti poruši toleranco za plod in poveča izgube plodov.
Other medicines and Nivolumab BMS 
Druga zdravila in zdravilo Nivolumab BMS
Nivolumab BMS is a medicine used to treat advanced non-small cell lung cancer (a type of lung cancer) in adults. 
Kaj je zdravilo Nivolumab BMS in za kaj ga uporabljamo Zdravilo Nivolumab BMS uporabljamo za zdravljenje napredovalega nedrobnoceličnega pljučnega raka (vrsta pljučnega raka) pri odraslih.
These additional biomarker analyses are occurring in the context of Study CA209-038 and Study CA209-066. 
Te dodatne analize bioloških označevalcev se izvedejo v okviru študije CA209-038 in študije
Patients with treated brain metastases were eligible if neurologically returned to baseline at least 2 weeks prior to enrolment, and either off corticosteroids, or on a stable or decreasing dose of <10 mg daily prednisone equivalents. 
Bolniki z zdravljenimi zasevki v možganih so bili primerni za vključitev, če se je nevrološko stanje povrnilo do izhodiščnega stanja vsaj 2 tedna pred vključitvijo in se niso zdravili s kortikosteroidi ali pa so se zdravili s stabilnim ali manjšajočim se odmerkom kortikosteroida, ki je
Tell your doctor immediately if you have any of these signs or symptoms or if they get worse. 
Če opazite katerega koli od teh znakov ali simptomov ali če znaki ali simptomi postajajo hujši, o tem nemudoma obvestite zdravnika.
Recommended treatment modifications for Nivolumab BMS 
Priporočene prilagoditve zdravljenja z zdravilom Nivolumab BMS
Survival benefit was observed regardless of whether patients had tumours that were designated PD-L1 negative or PDL1 positive (tumour membrane expression cut off of 1%, 5% or 10%). 
Korist za preživetje je bila opažena ne glede na PD-L1 negativno ali PD-L1 pozitivno označenost tumorja
There was no evidence of altered pharmacokinetic or toxicity profile associated with anti-product-antibody development. 
V povezavi z razvojem protiteles proti zdravilu niso ugotovili znakov spremenjenega farmakokinetičnega profila ali profila toksičnosti.
To further investigate at post-approval the possible change in PD-L1 status of the tumour during treatment and/or tumour progression in Studies CA209-009, CA209-038 and CA209-064. 
statusa tumorja med zdravljenjem in/ali napredovanjem tumorja v študijah CA209-009, CA209-038 in CA209-064.
For suspected immune-related adverse reactions, adequate evaluation should be performed to confirm aetiology or exclude other causes. 
V primeru suma na pojav imunsko pogojenih neželenih učinkov je treba z ustreznimi preiskavami potrditi njihov vzrok oziroma izključiti druge možne vzroke.
Each mL of this medicinal product contains 0.1 mmol (or 2.5 mg) sodium. 
En ml tega zdravila vsebuje 0,1 mmol (ali 2,5 mg) natrija.
Tel: + 39 06 50 39 61 
Tel: + 39 06 50 39 61 Nederland
Data from patients 75 years of age or older are too limited to draw conclusions on this population. 
Pri bolnikih, starih 75 let ali starejših, je na voljo premalo podatkov, zato zaključkov za to populacijo ne moremo navesti.
Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. 
Zdravilo Nivolumab BMS je indicirano za zdravljenje lokalno napredovalega ali metastatskega ploščatoceličnega nedrobnoceličnega pljučnega raka (NSCLC - non-small cell lung cancer) po
Patients with mild or moderate infusion reaction may receive nivolumab with close monitoring. 
Bolniki z blago ali zmerno infuzijsko reakcijo se z nivolumabom lahko zdravijo, vendar pa jih je med infundiranjem treba skrbno nadzirati.
For storage conditions after preparation of the infusion, see section 6.3. 
Za pogoje shranjevanja po pripravi raztopine za infundiranje glejte poglavje 6.3. 6.5 Vrsta ovojnine in vsebina
Stopping your treatment may stop the effect of the medicine. 
Ta zdravila lahko vplivajo na učinek zdravila
Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. 
Farmakoterapevtska skupina: Zdravila z delovanjem na novotvorbe (citostatiki), monoklonska
Infectious and disease-related aetiologies should be ruled out. 
Izključiti je treba okužbe in vzroke, povezane z boleznijo.
Uncommon bronchitis, upper respiratory tract infection Neoplasms benign, malignant and unspecified (including cysts and polyps) Uncommon histocytic necrotising lymphadenitis (Kikuchi lymphadenitis) Immune system disorders 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) občasni histiocitni nekrotizirajoči limfadenitis (Kikuchijev limfadenitis)
Body weight normalised dosing produced approximately uniform steady-state trough concentration over a wide range of body weights (34-162 kg). 
Z uporabo na telesno maso prilagojenih odmerkov zagotovimo približno enakomerno najmanjšo koncentracijo v stanju dinamičnega ravnovesja pri širokem razponu telesnih mas (od 34 do 162 kg).
Prophylactic antibiotics should be used to prevent opportunistic infections in patients receiving immunosuppressive therapy. 
Pri bolnikih, ki se zdravijo z zdravili za zaviranje imunske odzivnosti, je treba profilaktično uporabljati antibiotike za preprečevanje oportunističnih okužb.
Median time to onset was 11.6 weeks (range: 2.6-85.1). 
Mediani čas do pojava je znašal 11,6 tednov (razpon: 2,6-85,1).
Permanently discontinue Nivolumab BMS Note: Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4). 
Opomba: Stopnje toksičnosti so navedene v skladu z različico 4.0 terminološko poenotenih kriterijev neželenih učinkov ameriškega Nacionalnega onkološkega inštituta (NCI-CTCAE v4; “National Cancer Institute
Withhold Nivolumab BMS until symptoms resolve and management with corticosteroids (if needed for symptoms of acute inflammation) is complete. 
Aplikacijo zdravila Nivolumab BMS zadržite dokler simptomi ne izzvenijo in zdravljenje s kortikosteroidi (če je bilo potrebno za zdravljenje simptomov akutnega vnetja) ni končano.
Nivolumab 3 mg/kg showed an overall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of 8.21 months (95% CI: 6.05-10.9 months ), and a median PFS of 1.87 months (95% CI 1.77-3.15 months. 
Pri uporabi nivolumaba v odmerku 3 mg/kg je delež celokupnega odziva znašal 14,5 % (95 % interval zaupanja: 8,7-22,2 %), mediana celokupnega preživetja 8,21 meseca (95 % interval zaupanja: 6,05-10,9 meseca), mediana preživetja brez napredovanja bolezni pa 1,87 meseca (95 % interval zaupanja: 1,77-3,15 meseca.
The other ingredients are sodium citrate dihydrate, sodium chloride (see section 2 " Nivolumab BMS contains sodium"), mannitol (E421), pentetic acid, polysorbate 80, sodium hydroxide, hydrochloric acid and water for injections. 
Nivolumab BMS vsebuje natrij”), manitol (E421), pentetska kislina, polisorbat 80, natrijev hidroksid, klorovodikova kislina in voda za injekcije.
Severe infusion reactions have been reported in clinical trials (see section 4.8). 
V kliničnih preskušanjih so poročali o pojavu hudih infuzijskih reakcij (glejte poglavje 4.8).
Severe hepatitis has been observed with nivolumab treatment. 
Pri zdravljenju z nivolumabom so poročali o hudem hepatitisu.
Patients should be monitored for diarrhoea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool. 
Bolnike je treba nadzirati glede pojava driske in dodatnih simptomov kolitisa, kot so bolečina v trebuhu in sluz ali kri v blatu.
Take care to ensure aseptic handling when you prepare the infusion. 
Pri pripravi raztopine za infundiranje morate zagotoviti aseptične pogoje.
Nivolumab BMS infusion is compatible with: PVC containers 
Nivolumab BMS raztopina za infundiranje je kompatibilna z vsebniki iz PVC-ja in poliolefina,
There was no worsening to Grade 3 or 4 in increased ALT, increased alkaline phosphatase, and increased creatinine. 
O zvišanju vrednosti ALT, zvišanju vrednosti alkalne fosfataze in zvišanju vrednosti kreatinina stopnje 3 ali 4 niso poročali.
The effect of hepatic impairment on the CL of nivolumab was evaluated in patients with mild hepatic impairment (total bilirubin 1.0 × to 1.5 × ULN or AST > ULN as defined using the National Cancer Institute criteria of hepatic dysfunction; n = 92) compared to patients with normal hepatic function (total bilirubin and AST ≤ ULN; n = 804) in the population PK analyses. 
Vpliv okvare jeter na očistek nivolumaba so v analizah populacijske farmakokinetike ovrednotili pri bolnikih z blago okvaro jeter (skupni bilirubin 1,0 × do 1,5 × ZMN ali AST > ZMN po kriterijih ameriškega Nacionalnega onkološkega inštituta za disfunkcijo jeter; n = 92) v primerjavi z bolniki z normalnim delovanjem jeter (skupni bilirubin in AST ≤ ZMN; n = 804).
Nivolumab 3 mg/kg (events : 86/135), median and 95% CI : 9.23 (7.33, 13.27) 
Nivolumab 3 mg/kg (dogodki: 86/135), mediana in 95 % IZ: 9,23 (7,33; 13,27) Docetaksel (dogodki: 113/137), mediana in 95 % IZ: 6,01 (5,13; 7,33)
Before you are given Nivolumab BMS, tell your doctor if you are taking any medicines that suppress your immune system, such as corticosteroids, since these medicines may interfere with the effect of Nivolumab BMS. 
Preden boste prvič prejeli zdravilo Nivolumab BMS obvestite zdravnika, če jemljete katero koli zdravilo, ki zavira imunski sistem, kot so kortikosteroidi.
The total nivolumab dose in mg = the patient's weight in kg × the prescribed dose in mg/kg. 
Celotni odmerek nivolumaba v mg = telesna masa bolnika v kg × predpisani odmerek v mg/kg.
BRISTOL-MYERS SQUIBB POLSKA SP. Z O.O. 
Polska BRISTOL-MYERS SQUIBB POLSKA SP. Z O.O.
Although ECOG status, baseline glomerular filtration rate (GFR), albumin, body weight, and mild hepatic impairment had an effect on nivolumab CL, the effect was not clinically meaningful. 
Stanje telesne zmogljivosti po lestvici ECOG, izhodiščna ocena glomerulne filtracije (GFR - glomerular filtration rate), vrednost albumina, telesna masa in blaga okvara jeter so sicer imeli vpliv na očistek nivolumaba, vendar pa
Nivolumab BMS should not be infused concomitantly in the same intravenous line with other medicinal products. 
Zdravila Nivolumab BMS se ne sme infundirati sočasno z drugimi zdravili preko iste intravenske linije.
Baseline ECOG performance status score was 0 (24%) or 
Ocena stanja telesne zmogljivosti po lestvici ECOG v izhodišču je bila 0 (24 %) ali 1 (76 %).
The use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided because of their potential interference with the pharmacodynamic activity. 
Pred uvedbo zdravljenja z nivolumabom se je treba izogniti uporabi sistemskih kortikosteroidov in drugih zdravil za zaviranje imunske odzivnosti zaradi njihovega možnega vpliva na farmakodinamično aktivnost.
Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient. 
Zdravljenje mora trajati dokler je prisotna klinična korist oziroma dokler bolnik
Resolution occurred in 5 patients (71%), including the Grade 3 case, with a median time to resolution of 5.9 weeks (range: 0.7- 37.6+); + denotes a censored observation. 
Do izboljšanja je prišlo pri 5 bolnikih (71 %), vključno z bolnikom s primerom stopnje 3, mediani čas do izboljšanja pa je znašal 5,9 tednov (razpon: 0,7-37,6+); + označuje krnjene podatke.
Grade 2 cases were reported in 3.6% (9/248) of patients. 
O primerih stopnje 2 so poročali pri 3,6 % (9/248) bolnikov.
These include: A decreased number of red blood cells (which carry oxygen), white blood cells (which are important in fighting infection) or platelets (cells which help the blood to clot) Abnormal liver function tests (increased amounts of the liver enzymes aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase in your blood, higher blood 
zmanjšanje števila rdečih krvnih celic (celice, ki prenašajo kisik), belih krvnih celic (celice, ki so pomembne za obrambo pred okužbami) ali trombocitov (celice, ki so potrebne za normalno nenormalni izvidi preiskav delovanja jeter (zvišanje vrednosti jetrnih encimov aspartat-aminotransferaze, alanin-aminotransferaze ali alkalne fosfataze v krvi, zvišanje nenormalni izvidi delovanja ledvic (zvišanje vrednosti kreatinina v krvi) nenormalne vrednosti kalcija, kalija, magnezija ali natrija v krvi zvišanje vrednosti encima, ki razgrajuje maščobe, in zvišanje vrednosti encima, ki razgrajuje
In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth. 
Na izogenskih mišjih modelih se po zavrtju aktivnosti PD-1 rast tumorja
Nivolumab is unlikely to affect your ability to drive or use machines; however, use caution when performing these activities until you are sure that nivolumab does not adversely affect you. 
Vpliv na sposobnost upravljanja vozil in strojev Verjetnost vpliva nivolumaba na sposobnost upravljanja vozil in strojev je majhna, vendar pa morate biti vseeno pozorni, da nivolumab pri vas nima negativnih vplivov na tovrstne aktivnosti.